Collplant Biotechnologies Ltd's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 2550, above the company average. This is a clear sign of healthy business climate in the Medical Equipment & Supplies industry and improving liquidity at their respective customers, during the fourth quarter 2025. Average receivable collection period, for the Collplant Biotechnologies Ltd in Dec 31 2025 quarter, has decreased to 0 days, compared to 33 days, in the 0 quarter.

If we take a look into Healthcare sector 443 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2025 from to 3049.

What is Receivable Turnover Ratio?
What is Collplant Biotechnologies Ltd Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CLGN Receivables Turnover Ratio	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2024) II. Quarter
Y / Y Receivable Change	-99.33 %	-99.6 %	-	-	-98.52 %
Y / Y Revenue Change	852.21 %	-	-	-	-
Receivable Turnover Ratio (TTM)	2550	11.19	113.3	111.8	213.92
CLGN's Total Ranking	# 3049	#	#	#	#
Accounts Receivable average collection period days	0	33	3	3	2
Seq. Receivable Change	0 %	0 %	0 %	-99.33 %	-40 %
Seq. Revenue Change	-	-	-	-	-97.73 %

Receivable Turnover Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 150
Healthcare Sector	# 444
Overall Market	# 3049

Receivable Turnover Ratio Statistics
High	Average	Low
0.57	0.28	0.01
(Dec 31 2020)		(Dec 31 2022)

CLGN Company Profile • Back to CLGN Efficiency Comparisons • Compare CLGN Receivables Turnover Ratio to its Competitors

Financial Statements
Collplant Biotechnologies Ltd's Accounts Receivable	$ 0 Millions	Visit CLGN's Balance sheet
Collplant Biotechnologies Ltd's Sales TTM	$ 3 Millions	Visit CLGN's Income Statement
Sources of CLGN's Revenues		Visit CLGN's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
CLGN's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
CLGN's Growth Rates	CLGN's Roa	CLGN's Inventory Turnover Ratio	CLGN's Dividend Comparisons
CLGN's Profitability Ratios	CLGN's Roi	CLGN's Asset Turnover Ratio	CLGN's Dividend Growth
CLGN's Valuation Ratios	CLGN's Roe	CLGN's Financial Strength Ratios	CLGN's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2025	Receivable at quarter ending Dec 31 2025
Collplant Biotechnologies Ltd	2,371.00	$ 2.371 Millions	$ 0.001 Millions
Bicycle Therapeutics Plc	2,134.88	$ 72.586 Millions	$ 0.034 Millions
Ainos Inc	1,371.90	$ 0.124 Millions	$ 0.000 Millions
Adagene Inc	563.04	$ 7.671 Millions	$ 0.014 Millions

Date modified: 2026-09-04T17:23:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.